Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71057 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Saichun Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: First Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Aspart, Insulin Glargine. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi China Investment Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study. Materials and Methods In Soli‐D, Chinese adults with T2D suboptimally controlled on oral antidiabetic drugs (OADs) were randomized to iGlarLixi or IDegAsp for 24 weeks. These post hoc analyses evaluated glycaemic efficacy, insulin dose, body weight and hypoglycaemia outcomes in subgroups defined by baseline age (< 65, ≥ 65 years), T2D duration (< 10, ≥ 10 years) and HbA1c (≥ 7% to ≤ 8% [≥ 53 to ≤ 64 mmol/mol], > 8% to ≤ 9% [> 64 to ≤ 75 mmol/mol], > 9% [> 75 mmol/mol]).
Results
Among 582 participants (iGlarLixi n = 291; IDegAsp n = 291), baseline age was < 65 years in 442 and ≥ 65 years in 140; T2D duration was < 10 years in 366 and ≥ 10 years in 216; and HbA1c was ≥ 7% to ≤ 8% in 205, > 8% to ≤ 9% in 209 and > 9% in 168. At Week 24, HbA1c reductions were greater with iGlarLixi versus IDegAsp, with no treatment‐by‐subgroup interactions for baseline age, T2D duration or HbA1c. Change in other glycaemic outcomes, insulin dose and body weight generally showed no interaction across subgroups. Total insulin daily doses during treatment and hypoglycaemia event rates were consistently lower with iGlarLixi versus IDegAsp in all subgroups. Conclusions iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D on OADs, regardless of baseline age, disease duration or HbA1c.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Medical Center of PLA General Hospital, Beijing, China.
- Affiliated Hospital of Nantong University, Nantong, China.
- Sanofi, Madrid, Spain.
- Sanofi, Paris, France.
- Ividata Life Sciences, Paris, France.
- Sanofi, Shanghai, China.
Förderung
- Sanofi China Investment Company
Zitieren
APA
Zhang, S., Gu, Y., Cheng, Y., Hu, Y., Li, B., Alvarez, A., Lauand, F., Melas-Melt, L., Zhang, M., Jiang, Y., Du, Q., Kang, L., Mu, Y., Gu, W., & Kuang, H. (2026). Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71057
Vancouver
Zhang S, Gu Y, Cheng Y, Hu Y, Li B, Alvarez A, et al. Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71057
BibTeX
@article{Zhang2026,
author = {Zhang, Saichun and Gu, Yunjuan and Cheng, Yu and Hu, Ying and Li, Bing and Alvarez, Agustina and Lauand, Felipe and Melas-Melt, Lydie and Zhang, Minlu and Jiang, Yini and Du, Qin and Kang, Lei and Mu, Yiming and Gu, Weijun and Kuang, Hongyu},
title = {Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71057}
}
EUVIMED